Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Switching from the ritonavir-boosted protease inhibitor component to raltegravir in stable
HIV-infected adult patients receiving combination therapy will demonstrate improved clinical
tolerability or lipid profiles with sustained plasma virological response (<50 copies/ml).
Phase:
Phase 4
Details
Lead Sponsor:
Lin, Hsi-Hsun, M.D.
Treatments:
HIV Protease Inhibitors Protease Inhibitors Raltegravir Potassium Reverse Transcriptase Inhibitors